Libroxar (Buprenorphine, Naloxone)

Libroxar (buprenorphine/naloxone) is used in the management of opioid dependence, targeting the opioid receptor system.

• Opioid dependence: reduces withdrawal symptoms and cravings during maintenance therapy.
• Opioid use disorder: supports long‑term abstinence and prevents relapse.
• Opioid detoxification: facilitates safe transition off full‑agonist opioids under medical supervision.

• Buprenorphine binds with high affinity to the μ‑opioid receptor as a partial agonist, providing sufficient receptor activation to relieve withdrawal while limiting maximal opioid effect; it also antagonizes κ‑opioid receptors. Naloxone, poorly absorbed sublingually, acts as an opioid antagonist that becomes active if the product is injected, blocking opioid effects and deterring misuse.

Libroxar may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects

• Headache: mild to moderate head pain.
• Nausea: feeling of queasiness.
• Constipation: reduced bowel movements.
• Sweating: increased perspiration.
• Dizziness: light‑headed sensation.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Respiratory depression: severe slowing of breathing.
• Severe hypotension: marked drop in blood pressure.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Liver enzyme elevation: abnormal liver function tests.

Before prescribing Libroxar, clinicians should consider several safety measures.

• Assess dependence severity: evaluate opioid use history before initiating.
• Monitor for withdrawal: watch for signs of precipitated withdrawal especially if recent opioid use.
• Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol.
• Pregnancy and lactation: weigh benefits against potential risks.
• Renal or hepatic impairment: adjust therapy as clinically indicated.
• Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Libroxar can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

• Benzodiazepines: combined use can cause profound respiratory depression.
• Other opioids: may precipitate withdrawal or increase toxicity.
• CYP3A4 inhibitors (e.g., ketoconazole): raise buprenorphine levels.
• Alcohol: additive central nervous system depression.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin): may reduce effectiveness.
• Antidepressants (e.g., SSRIs): monitor for serotonin syndrome.
• Antihistamines: may increase sedation.
• Anticonvulsants (e.g., carbamazepine): may lower plasma levels.